UHN Collaborative Centre for Drug Discovery (C2D2) Launch Symposium

Join us live for the UHN C2D2 Launch Symposium to dive into exciting drug discovery breakthroughs!
About this Event

UHN Collaborative Centre for Drug Discovery (C2D2) Launch Symposium

Join us for the official launch of the Collaborative Centre for Drug Discovery (C2D2)—a new initiative focused on advancing disease-driven drug discovery at UHN.

This symposium brings together leading researchers, clinicians, and partners from across UHN, the Structural Genomics Consortium, and the broader Toronto research community.

Why attend

• Hear from prominent researchers and clinicians across UHN
• Explore new opportunities in translational and small-molecule drug discovery
• Connect with researchers and clinicians across disciplines
• Engage in discussions shaping the future of therapeutic discovery at UHN

Event details

Date: June 9, 2026
Time: 8:30 a.m. – 4:00 p.m.
Location: MaRS Auditorium, 101 College St, Toronto

Registration: Free (advance registration required)

Food & Beverage will be provided.

About C2D2

The Collaborative Centre for Drug Discovery (C2D2) is a synergistic collaboration between SGC-Toronto and UHN Therapeutics that aims to translate discoveries in disease biology into actionable drug targets. By combining expertise in small-molecule development with clinical and research collaboration, C2D2 enables new therapeutic strategies and accelerates promising discoveries toward impact. Visit our website for more details: https://www.uhnresearch.ca/service/uhn-collaborative-centre-for-drug-discovery

Launch Symposium comments and inquiries can be sent to [email protected].

Agenda

🕑: 08:00 AM - 08:30 AM
Registration; Coffee/Tea & Breakfast
🕑: 08:30 AM - 08:40 AM
Opening Remarks: Dr. Jaideep Bains
🕑: 08:40 AM - 08:50 AM
Opening Remarks: Dr. Cheryl Arrowsmith & Dr. Mark Reed
🕑: 08:50 AM - 09:10 AM
SGC and Target 2035: Priming the Pipeline for Accelerated Drug Discovery
Host: Cheryl Arrowsmith
🕑: 09:10 AM - 09:30 AM
E-ASMS Enables Discovery of a Potent HAT1 Inhibitor
Host: Levon Halabelian
🕑: 09:30 AM - 09:50 AM
High-Throughput Biophysical Screening for Early Drug Discovery
Host: Oleksandra Herasymenko
🕑: 09:50 AM - 10:20 AM
Coffee Break & Poster Viewing
🕑: 10:20 AM - 10:40 AM
Enabling Targeted Protein Degradation with Proteomics & Chemical Probes
Host: Matthew Maitland
🕑: 10:40 AM - 11:00 AM
DEL-Based Discovery & Structural Analysis of a Human TMPRSS12 Inactivator
Host: Bryan Fraser
🕑: 11:00 AM - 11:20 AM
Climbing the Scaffold: RaPID-Derived Cyclic Peptides for Chemical Biology
Host: Esther Wolf
🕑: 11:20 AM - 12:40 PM
Lunch & Poster Viewing
🕑: 12:40 PM - 01:00 PM
UHN Therapeutics & C2D2
Host: Mark Reed
🕑: 01:00 PM - 01:20 PM
In Pursuit of an Anti-Radiation Fibrosis Drug
Host: Fei-Fei Liu
🕑: 01:20 PM - 01:40 PM
Using Chemical Proteomics to Identify Novel Neuroprotective Mediators
Host: Jeremy Sivak
🕑: 01:40 PM - 02:00 PM
Validation of TRPM2 as a Novel Therapeutic Target for Rett Syndrome
Host: James Eubanks
🕑: 02:00 PM - 02:30 PM
Coffee Break
🕑: 02:30 PM - 02:50 PM
Targeting the Damaged Transcriptome in High Grade Serous Ovarian Cancer
Host: Robert Rottapel
🕑: 02:50 PM - 03:10 PM
Targeting Altered RNA Processing in Leukemic Stem Cells
Host: Kristin Hope
🕑: 03:10 PM - 03:30 PM
The In Silico Search for Endogenous anti-Alzheimer's Agents
Host: Donald Weaver
🕑: 03:30 PM - 03:50 PM
C2D2 Panel: How C2D2 Can Advance UHN Drug Discovery Efforts
Host: Cheryl Arrowsmith & Mark Reed
🕑: 03:50 PM - 04:00 PM
Closing Remarks: Dr. Cheryl Arrowsmith & Dr. Mark Reed